Purpose There are clinical unmet needs in predicting therapeutic response and precise strategy for the patient with advanced biliary tract cancer (BTC). We aimed to identify genomic alterations predicting therapeutic response and resistance to gemcitabine and cisplatin (Gem/Cis)-based chemotherapy in advanced BTC.
Materials and Methods Genomic analysis of advanced BTC multi-institutional cohorts was performed using targeted panel sequencing. Genomic alterations were analyzed integrating patients’ clinicopathologic data, including clinical outcomes of Gem/Cis-based therapy. Significance of genetic alterations was validated using clinical next-generation sequencing (NGS) cohorts from public repositories and drug sensitivity data from cancer cell lines.
Results 193 BTC patients from three cancer centers were analyzed. Most frequent genomic alterations were TP53 (55.5%), KRAS (22.8%), ARID1A (10.4%) alterations, and ERBB2 amplification (9.8%). Among 177 patients with BTC receiving Gem/Cis-based chemotherapy, ARID1A alteration was the only independent predictive molecular marker of primary resistance showing disease progression for 1st-line chemotherapy in the multivariate regression model (odds ratio, 3.12; p=0.046). In addition, ARID1A alteration was significantly correlated with inferior progression-free survival on Gem/Cis-based chemotherapy in the overall patient population (p=0.033) and in patients with extrahepatic cholangiocarcinoma (CCA) (p=0.041). External validation using public repository NGS revealed that ARID1A mutation was a significant predictor for poor survival in BTC patients. Investigation of multi-OMICs drug sensitivity data from cancer cell lines revealed that cisplatin-resistance was exclusively observed in ARID1A mutant bile duct cancer cells.
Conclusion Integrative analysis with genomic alterations and clinical outcomes of the first-line Gem/Cis-based chemotherapy in advanced BTC revealed that patients with ARID1Aalterations showed a significant worse clinical outcome, especially in extrahepatic CCA. Well-designed prospective studies are mandatory to validate the predictive role of ARID1Amutation.
Citations
Citations to this article as recorded by
ARID1A in Gynecologic Precancers and Cancers Jaida E. Morgan, Nishah Jaferi, Zainab Shonibare, Gloria S. Huang Reproductive Sciences.2024; 31(8): 2150. CrossRef
Genomic analysis of bladder urothelial carcinoma with osteoclast‑like giant cells: A case report Koji Kameyama, Kosuke Mizutani, Tetsuya Yamada, Seiji Sugiyama, Shingo Kamei, Shigeaki Yokoi, Kengo Matsunaga, Koseki Hirade, Yasutaka Kato, Hiroshi Nishihara, Satoshi Ishihara, Takashi Deguchi Molecular and Clinical Oncology.2024;[Epub] CrossRef
A mutational signature and ARID1A mutation associated with outcome in hepatocellular carcinoma Wei Zhou, Hao Chi, Xiaohu Zhao, Guangrong Tao, Jianhe Gan Clinical and Translational Oncology.2024;[Epub] CrossRef
Concordance of ctDNA and tissue genomic profiling in advanced biliary tract cancer Sohyun Hwang, Seonjeong Woo, Beodeul Kang, Haeyoun Kang, Jung Sun Kim, Sung Hwan Lee, Chang Il Kwon, Dong Soo Kyung, Hwang-Phill Kim, Gwangil Kim, Chan Kim, Hong Jae Chon Journal of Hepatology.2024;[Epub] CrossRef
Advances in the study of the role of high-frequency mutant subunits of the SWI/SNF complex in tumors Jiumei Zhao, Jing Zhu, Yu Tang, Kepu Zheng, Ziwei Li Frontiers in Oncology.2024;[Epub] CrossRef
The role of ARID1A in malignant neoplasms of the female reproductive system: a modern view on diagnostic and therapeutic opportunities A. I. Marzaganova, I. R. Martirosyan, A. S. Korchemkina, E. G. Avanesyan, D. A. Korkmazova, O. B. Grakhnova, V. V. Akimina, A. P. Dzhamalutdinova, D. A. Bolloev, A. M. Dugulbgova, Z. G. Bakhmudova, A. T. Salikhova, P. A. Dzigora Obstetrics, Gynecology and Reproduction.2024;[Epub] CrossRef
von Hippel–Lindau (VHL) disease is an autosomal dominant inherited tumor syndrome associated with mutations of the VHL tumor suppressor gene located on chromosome 3p25. The loss of functional VHL protein contributes to tumorigenesis. This condition is characterized by development of benign and malignant tumors in the central nervous system (CNS) and the internal organs, including kidney, adrenal gland, and pancreas. We herein describe the case of a 74-year-old man carrying the VHL gene mutation who was affected by simultaneous colorectal adenocarcinoma, renal clear cell carcinoma, and hemangioblastomas of CNS.
Citations
Citations to this article as recorded by
Diversities of Mechanism in Patients with VHL Syndrome and diabetes: A Report of Two Cases and Literature Review Yanlei Wang, Zhaoxiang Liu, Wenhui Zhao, Chenxiang Cao, Luqi Xiao, Jianzhong Xiao Diabetes, Metabolic Syndrome and Obesity.2024; Volume 17: 1611. CrossRef
Sporadic Renal Hemangioblastoma: A Case Report of a Rare Entity Fnu Raja, Vinesh Kumar, Azzam Hammad, Caroline Abramovich Cureus.2023;[Epub] CrossRef
VHL syndrome without clear family history: A rare case report and literature review of Chinese patients Yaheng Li, Xiaohong Xin, Wenzhu Song, Xuan Zhang, Shengli Chen, Qian Wang, Aizhong Li, Yafeng Li Frontiers in Neurology.2022;[Epub] CrossRef
Von Hipple-Lindau disease complicated with central retinal vein occlusion: a case report Xingwang Chen, Mengyao Wang, Yuan Tang, Bing Xie, Xiaomei Nie, Shanjun Cai BMC Ophthalmology.2022;[Epub] CrossRef
Whole-Exome Sequencing Reveals Novel Variations in Patients with Familial Von Hippel−Lindau Syndrome Yuhao Zhou, Jian Liu, Liangzhao Chu, Minghao Dong, Luqian Feng World Neurosurgery.2021; 150: e696. CrossRef
Sporadic renal hemangioblastoma: A case report of a rare benign renal tumor Lukas Oberhammer, Michael Josef Mitterberger, Lukas Lusuardi, Thomas Kunit, Martin Drerup, Daniela Colleselli, Hubert Griessner, Martina Hager Clinical Case Reports.2019; 7(12): 2321. CrossRef
MicroRNA Assisted Gene Regulation in Colorectal Cancer Adewale Fadaka, Ashley Pretorius, Ashwil Klein International Journal of Molecular Sciences.2019; 20(19): 4899. CrossRef